Revolution Medicines, Inc. announced the pricing of a concurrent public offering of common stock and a convertible senior note issuance on April 15 2026. The company sold 10,563,381 shares of common stock at a public offering price of $142.00 per share, generating aggregate gross proceeds of approximately $1.5 billion. The equity offering was upsized from an earlier plan of $750 million, and underwriters were granted a 30‑day option to purchase up to an additional 1,584,506 shares.
In parallel, Revolution Medicines issued $500 million of 0.50% convertible senior notes due 2033. The notes carry a coupon of 0.50% and a maturity date of 2033. The initial conversion rate is 5.0302 shares per $1,000 principal amount, implying an initial conversion price of about $198.80 per share, a premium of roughly 40% over the public offering price. The note offering was also upsized from an earlier plan of $250 million, reflecting strong investor demand for the company’s debt security.
The stock offering is scheduled to settle on April 16 2026, while the convertible notes will settle on April 17 2026, subject to customary closing conditions. The timing of the settlements aligns with the company’s cash‑flow planning and regulatory requirements for public offerings.
Proceeds from both the equity and debt offerings are earmarked for general corporate purposes, including research and development, commercialization of product candidates, and general and administrative expenses. The capital raised will extend the company’s runway for its Phase III clinical trials and support the development of its platform‑based RAS(ON) inhibitor program, which has attracted significant investor interest.
The financing event is a key milestone for Revolution Medicines, providing a substantial liquidity cushion that will enable the company to pursue its ambitious pipeline. The upsizing of both the equity and note offerings signals robust demand from institutional investors and confidence in the company’s scientific platform, particularly in light of the positive topline results from the Phase 3 RASolute 302 trial for daraxonrasib released earlier in April. These results demonstrate a statistically significant improvement in progression‑free and overall survival for patients with metastatic pancreatic ductal adenocarcinoma, positioning daraxonrasib as a potential first‑in‑class therapy.
The $2 billion in gross proceeds represents a significant expansion of Revolution Medicines’ capital base, which is critical for a late‑stage oncology company that has yet to generate revenue. The additional funds will support ongoing clinical development, potential commercialization activities, and general corporate needs, thereby strengthening the company’s financial position and strategic flexibility.
In summary, the concurrent equity and convertible note offerings underscore Revolution Medicines’ ability to secure capital in a competitive market and reinforce its commitment to advancing its RAS inhibitor pipeline. The financing provides the resources necessary to sustain the company’s clinical program and positions it for future growth as it moves closer to regulatory approval and potential market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.